Abstract
Abstract Pediatric brain tumors are the number one cause of cancer-related death in children, with medulloblastoma (MB) being the most common type. Genomic-based classification has enabled the stratification of MB into four distinct molecular subgroups: WNT, Sonic Hedgehog, Group 3, and Group 4. Such classification allows a better understanding of these malignancies, which has resulted in a significant improvement in the stratification of clinical trials. Despite substantial progress made in the field, still, 30% of children with MB will relapse. Recurrent disease in MB is commonly metastatic and virtually none of these patients will live beyond the 1-year hallmark. These sobering statistics underscore the largely unmet need for brain tumor therapies aimed at treating or preventing the emergence of relapsed disease. In this session, we will review recent advances in the identification of treatment-resistant pools of brain tumor cells, giving special emphasis to the signaling mechanisms that allow these cell populations to evade therapeutics and expand. Citation Format: Jezabel Rodriguez-Blanco. Mechanistic insights of brain tumor relapse. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr SY23-02.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
